Saniona starts 2022 with three clinical trials

Saniona begins 2022 with three clinical trials ongoing

During 2021 Saniona succeeded in the feat of initiating three clinical trials. One phase I study with SAN711 for the treatment of rare neuropathic...
Chordate Medical

Chordate Medical closed 2021 with focus on Saudi Arabia

Patients with chronic nasal congestion in Saudi Arabia can receive full reimbursement for Chordate Medical’s K.O.S treatment, which was recently performed for the first...
RhoVac är snart klara med sin rekrytering

BioInvent presents additional positive study data

Bioinvent, who on January 3rd will be moved up to Nasdaq Stockholm's Mid Cap segment, has presented positive early data from the ongoing study...
Idogen

Idogen submits clinical trial application

Last week, biotech company Idogen submitted a clinical trial application to the Swedish Medical Products Agency to initiate a clinical phase I/IIa study with...

CombiGene’s CEO about the path to the first clinical trial

CombiGene recently strengthened its gene therapy project CG01 in the best possible way when it signed an exclusive, global collaboration and licensing agreement with...
Cyxone enters EOA with a CRO

Cyxone’s CRO agreement signal phase IIb RA trial is moving forward...

In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations Agreement with...
Cereno Scientific expands patent rights for CS1

Cereno Scientific expands patent rights for CS1

With Cereno Scientific’s lead programme CS1 currently in phase II, the company is working towards future-proofing its commercial positioning. Throughout 2021, the biotech company...
Elicera Therapeutics partners with Baylor College of Medicine

Elicera Therapeutics partners with Baylor College of Medicine

Elicera Therapeutics has been gearing up for new clinical trials with its cancer cell and gene therapy projects. As part of that journey, the...
Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs sees first patient enrolled in DOVACC trial

Ultimovacs has announced that the first patient has been enrolled in a phase II trial designed to assess the impact of the company’s universal...
Erik Kinnman, CEO Sprint Bioscience

Sprint Bioscience invests to expand portfolio and number of deals

Huddinge-based Sprint Bioscience has had an eventful 2021 to say the least. In the face of the success of the past year, the company...